Seleccione idioma:  
RTICC 2013
Programas RTICC
Seguimiento cientifico
Sobre la RTICC 2013-2016 » Presentación

The current proposal for an ISCIII-sponsored RETIC on cancer for the period 2013-2016 reflects the natural evolution of prior experiences of cooperative cancer research networks previously held in Spain on a continuous basis since 2003. In particular, an initial Network of Cancer Research Centers (Red Temática de Investigación Cooperative de Centros de Cancer, RTICCC) was established during the years 2003-2006 that encompassed 23 separate institutions research centers (126 individual groups) located in different hospitals and research centers located of 12 different autonomous regions of Spain. Since 2006, the Spanish Cancer Network switched focus from the research centers to the individual lPI-led groups and a new Red Temática de Investigación Cooperativa en Cancer, RTICC, was established that involved the cooperative work of 95 distinct, PI-led groups (85 Regular groups, and 15 clinical associate groups) distributed in institutions located in 13 different CCAA of this country. Despite its initial conception as 4 year project, the ISCIII has extended the activities and validity of the current RTICC has extended its activities for a total 6 years, until the end of 2012. The current proposal for a new RETIC on cancer is being presented by the 20-member Executive Committee of the current RTICC, in an effort to extend and improve on the quality and results yields of the research efforts of the Cancer research cooperative in our country.

It is also pertinent to mention that the Strategic Action Plan presented in this document represents a natural continuation of the Strategic Action Plans that were implemented and refined periodically in the RTICC network in response to the yearly evaluations and recommendations received during the period 2007-2012 from either ad hoc external evaluation agencies commissioned by ISCIII or from its own external Scientific Advisory Board. As many of those recommendations were geared at improving the scientific quality and international competitiveness of the RTICC network components, the current proposal reflects an emphasis on (i) the translational orientation of basic, clinical and epidemiological research tasks planned for the network as well as on (ii) the lower number, (iii) bigger size and (iv)higher scientific productivity of the groups selected to participate in this initiative. In this regard it is worth mentioning that the list of groups participating in the current proposal is composed by (i) a majority (about 80%) of RTICC groups that were consistently evaluated in the top 50% of that network and a (ii) smaller group (about 15%) of new, high quality research groups that were not previously part of RTICC as they were integrated in research structures (such as Consoliders) that were deemed incompatible with the RETICs by ISCIII (to which they have now resigned).

Preparing, writing and editing the present cancer RETIC proposal has been the result of a consensus-building process managed by the Executive Committee of RTICC and the joint work of a designated ad hoc subcommittee. This process has entailed the application of consensus criteria for the definition and formulation of the 8 research Programs composing this proposal as well as to the selection of candidates groups and PIs and to all other organizational details of each one of the Programs. Geared to improving synergyzation and enhancement of the quality of cancer research performed by individual groups at the national level. Consistent with the significantly reduced budget available for the current RETIC call, only a total 70 groups have been selected for participation in this call (about 30% reduction in comparison to the number of groups participating in the RTICC network ending December 2012).

Work Packages
Coordinación RTICC
03/03/2017 | Otras reuniones
13/11/2016 | Otras reuniones
NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease.
Martinez D, Navarro A, Martinez-Trillos A, Molina-Urra R, Gonzalez-Farre B, Salaverria I, Nadeu F, Enjuanes A, Clot G, Costa D, Carrio A, Villamor N, Colomer D, Martinez A, Bens S, Siebert R, Wotherspoon A, Beà S, Matutes E, Campo E
Am J Surg Pathol  2016.  2.  192-201.  PMID: 26426381. 
Grupos colaboradores: RD12/0036/0036 , RD12/0036/0023

Present and future of personalized medicine in CLL.
Montserrat E, Bauman T, Delgado J
Best Pract Res Clin Haematol  2016.  1.  100-110.  PMID: 27742064. 

Maintenance therapy in chronic lymphocytic leukaemia.
Delgado J, Montserrat E
Lancet Haematol  2016.  9.  e399-400.  PMID: 27570083. 

[Advances in the treatment of chronic lymphocytic leukaemia].
Mozas P, Delgado J
Med Clin (Barc)  2016.  10.  447-454.  PMID: 27431885. 

The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia.
Ortíz-Maldonado V, Mozas P, Delgado J
Ther Adv Hematol  2016.  6.  321-329.  PMID: 27904736. 

The European Hematology Association Roadmap for European Hematology Research: a consensus document.
Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ, EHA Roadmap for European Hematology Research.
Haematologica  2016.  2.  115-208.  PMID: 26819058. 

Diffuse Large B-Cell Lymphoma: Should Limited-Stage Patients Be Treated Differently?
Giné E, Sehn LH
Hematol Oncol Clin North Am  2016.  6.  1179-1194.  PMID: 27888874. 

Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage.
Queirós AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, Raineri E, Russiñol N, Castellano G, Beà S, Navarro A, Kulis M, Verdaguer-Dot N, Jares P, Enjuanes A, Calasanz MJ, Bergmann A, Vater I, Salaverría I, van de Werken HJ, Wilson WH, Datta A, Flicek P, Royo R, Martens J, Giné E, Lopez-Guillermo A, Stunnenberg HG, Klapper W, Pott C, Heath S, Gut IG, Siebert R, Campo E, Martín-Subero JI
Cancer Cell  2016.  5.  806-821.  PMID: 27846393. 
Grupos colaboradores: RD12/0036/0063 , RD12/0036/0036 , RD12/0036/0023

Genetic evolution in chronic lymphocytic leukaemia.
Delgado J, Villamor N, López-Guillermo A, Campo E
Best Pract Res Clin Haematol  2016.  1.  67-78.  PMID: 27742073. 
Grupos colaboradores: RD12/0036/0036 , RD12/0036/0023

Martín-Vañó S, Berbegall AP, Navarro L, Blanquer-Maceiras M, Beléndez-Bieler C, Garrido-Colino C, Navarro S, Rosa Noguera Salvá

Ministerio de Economia y Competitividad
Red Temática Investigación Cooperativa Sanitaria
Rticc 2012
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer - Campus Miguel de Unamuno - 37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es
Sobre la RTICC Programas RTICC Ofertas de empleo y Agenda Seguimiento científico
Red Temática de Investigación Cooperativa en Cáncer · © Copyright 2013 · sec.rticc[arrroba]usal.es · diseño web: detrazos